IGF-DES: Truncated IGF-1 Analog and Receptor Binding Research Guide

IGF-DES (Des(1-3)-IGF-1) is a naturally occurring N-terminal truncated variant of insulin-like growth factor 1 (IGF-1) that exhibits enhanced receptor-binding affinity compared to native IGF-1, making it a highly studied compound in growth factor and anabolic signaling research. Composition: 67 amino acids (7.4 kDa molecular weight) — three N-terminal amino acids (Gly-Pro-Glu) removed relative to native IGF-1. Key Structural Features: - N-terminal truncation eliminates the first three amino acid residues (des(1-3)) - Altered N-terminal domain disrupts IGFBP (insulin-like growth factor binding protein) interaction - Preserved C-domain and A-domain maintain full IGF-1R binding epitopes - Enhanced receptor affinity relative to both native IGF-1 and IGF-1 LR3 IGFBP Interaction: Significantly reduced binding to IGFBP-1, -2, and -3 due to N-terminal truncation, resulting in higher free peptide fraction in biological assays. IGF-DES binds the IGF-1 receptor with approximately 2-10x greater affinity than native IGF-1, depending on assay conditions. The N-terminal truncation removes a domain that normally contacts IGFBPs but also slightly modifies receptor interaction geometry, favoring direct IGF-1R engagement. - PI3K/Akt/mTOR axis: Core anabolic signaling for protein synthesis and cell growth - MAPK/ERK pathway: Cell proliferation, differentiation, and mitogenic signaling - Insulin receptor cross-reactivity: Moderate IR binding (lower than native IGF-1) due to structural changes Unlike native IGF-1 (which is 99% bound to IGFBPs in physiological conditions), IGF-DES's truncated N-terminus sterically disrupts the IGFBP binding interface. This produces a compound with dramatically higher bioactive fraction available for IGF-1R engagement at any given concentration. | Parameter | Native IGF-1 | IGF-1 LR3 | IGF-DES | |-----------|-------------|-----------|---------| | Molecular Weight | 7.6 kDa | 9.1 kDa | 7.4 kDa | | IGF-1R Binding Affinity | Reference | Similar to native | 2-10x greater | | IGFBP Affinity | High | 500x reduced | Significantly reduced | | Half-life | Minutes | 20-30 hours | Short (minutes) | | IGFBP Mechanism | Full binding | Arg3 substitution | N-terminal truncation | | Bioactive Fraction | Low (1%) | High | High | IGF-DES is extensively used to study receptor occupancy dynamics due to its high binding affinity. Researchers pair it with longer-acting IGF-1 analogs (such as IGF-1 LR3) to create comparative models of receptor engagement across different kinetic profiles. The compound's enhanced affinity and IGFBP bypass make it valuable for: - Downstream PI3K/Akt/mTOR pathway activation research - Satellite cell activation and muscle fiber formation studies - Protein synthesis rate modeling IGF-DES allows researchers to isolate the contribution of IGFBP interaction vs. intrinsic receptor affinity in IGF-1 signaling — a mechanistically important distinction from IGF-1 LR3 (which reduces IGFBP affinity via arginine subs